Cartesian Therapeutics (NASDAQ:RNAC) Receives Buy Rating from Needham & Company LLC
Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at ...
H.C. Wainwright maintains $45 target on Cartesian stock
H.C. Wainwright reaffirmed a Buy rating on Cartesian Therapeutics shares, maintaining the $45.00 price target, representing a ...
Strong Outlook for Cartesian Therapeutics: FDA SPA Agreement and Positive Phase 2b Results Boost Confidence in Descartes-08
Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated ...
PharmaTimes2d
Cartesian Therapeutics announces FDA agreement for new trial
Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol ...
Buy Rating for Cartesian Therapeutics: Promising Phase 3 Prospects for Descartes-08 in Treating Myasthenia Gravis
Julian Harrison, an analyst from BTIG, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated price ...
Engineering Immunity: The Breakthroughs Driving The CAR T-Cell Therapy Market (Growing At A CAGR Of 13.5%)
The CAR T-cell therapy market size was valued at $2.6 billion in 2022 and is estimated to reach $35.9 billion by 2032, exhibiting a CAGR of 28.5% by 2032.
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis
Trial on track to commence in 1H25FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA ...